Shots:

• Lilly will get an exclusive license to perform clinical development- manufacturing and distribution of products outside of China while Junshi will maintain all rights in Greater China
• The collaboration will accelerate the clinical development of Junshi’s Ab therapies against COVID-19 globally. Both the companies have submitted the IND application and anticipate the initiation of clinical study in Q2’20
•  JS016 is a recombinant mAb targeting SARS-CoV-2 surface spike protein receptor binding domain and effectively blocks the binding of viruses to host cell surface receptor ACE2 and is jointly developed by Junshi and Institute of Microbiology- Chinese Academy of Science. The company is in communication with NMPA to initiate the IND submission in China

Click here ­to­ read full press release/ article | Ref: Eli Lilly | Image:  Business Insider